This company has been marked as potentially delisted and may not be actively trading. NASDAQ:IMDZ Immune Design (IMDZ) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Immune Design Stock (NASDAQ:IMDZ) 30 days 90 days 365 days Advanced Chart Get Immune Design alerts:Sign Up Key Stats Today's Range$5.85▼$5.8550-Day Range$5.85▼$5.8552-Week Range$1.10▼$5.85VolumeN/AAverage Volume374,216 shsMarket Capitalization$282.96 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma. The company is also developing CA21, a multi-targeting prime boost for the treatment of multiple solid tumors; and ZVex-IL12 for the treatment of TBD tumors. In addition, its technologies are used in the fields of infectious and allergic diseases. The company has license agreements with California Institute of Technology, University of North Carolina at Chapel Hill, TheraVectys SA, Infectious Disease Research Institute, MedImmune LLC, and Sanofi; and a collaboration agreement with Sanofi Pasteur. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington. Read More Receive IMDZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immune Design and its competitors with MarketBeat's FREE daily newsletter. Email Address IMDZ Stock News HeadlinesNew antibody design enhances immune system's ability to fight cancerMay 2, 2025 | msn.comAI Reveals How Titanium Surfaces Steer Immune Responses in Implant DesignApril 11, 2025 | msn.comThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.July 10 at 2:00 AM | Weiss Ratings (Ad)Engineered immune cells may be able to tame inflammationDecember 6, 2024 | msn.comLab-Grown Human Immune System Uncovers Weakened Response in Cancer PatientsNovember 13, 2024 | msn.comExploring the circadian influence of immune cells on metabolic health and fat storageNovember 7, 2024 | msn.comDeciphering the mechanisms of immune response with probabilistic graphical networksNovember 6, 2024 | msn.comImmune system review provides insight into more effective biotechnologyOctober 31, 2024 | msn.comSee More Headlines IMDZ Stock Analysis - Frequently Asked Questions How were Immune Design's earnings last quarter? Immune Design Corp. (NASDAQ:IMDZ) posted its quarterly earnings data on Wednesday, August, 1st. The biotechnology company reported ($0.29) earnings per share for the quarter, beating analysts' consensus estimates of ($0.30) by $0.01. The biotechnology company earned $0.76 million during the quarter, compared to analyst estimates of $0.64 million. Immune Design had a negative trailing twelve-month return on equity of 49.56% and a negative net margin of 2,483.00%. What other stocks do shareholders of Immune Design own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immune Design investors own include Omeros (OMER), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX), Selecta Biosciences (SELB), TG Therapeutics (TGTX) and TherapeuticsMD (TXMD). Company Calendar Last Earnings8/01/2018Today7/10/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:IMDZ CIK1437786 Webwww.immunedesign.com Phone206-682-0645FaxN/AEmployees48Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$54.76 million Net Margins-2,483.00% Pretax MarginN/A Return on Equity-49.56% Return on Assets-46.21% Debt Debt-to-Equity RatioN/A Current Ratio11.33 Quick Ratio11.32 Sales & Book Value Annual Sales$2.20 million Price / Sales128.62 Cash FlowN/A Price / Cash FlowN/A Book Value$1.91 per share Price / Book3.06Miscellaneous Outstanding Shares48,370,000Free FloatN/AMarket Cap$282.96 million OptionableOptionable Beta3.48 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:IMDZ) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immune Design Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immune Design With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.